Incretin-based therapy and pancreatitis-what is the risk?

Endocrine Practice

Volumn 17, Issue 3, 2011, Pages 334-336

  Sternthal, Elliot ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INCRETIN; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ACUTE PANCREATITIS; BILIARY TRACT DISEASE; COMMON BILE DUCT OBSTRUCTION; EDITORIAL; HORMONAL THERAPY; HUMAN; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; POST HOC ANALYSIS; UNITED STATES;

EID: 79959677863     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11126.ED     Document Type: Editorial

References (29)

1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168:2088-2094.
2. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract. 2011;17:e48-e50.
3. Kothny W. Vildagliptin therapy in not associated with an increased risk of pancreatitis. Presented at: 45th Annual Meeting of the European Association for the Study of Diabetes. October 2009; Vienna, Austria. Abstract 769.
4. US Food and Drug Administration. Medwatch 2009 safety alerts for sitagliptin. Available at: Http://www.fda.gov/Safety/MedWatch/SafetyInformation/ ucm183800.htm. Accessed for verification May 31, 2011.
5. PatientsVille.com. Saxagliptin side effects. Available at: Http://www.patientsville.com/medication/saxagliptin-side-effects.htm.
6. Buse JB, Rosenstock J, Sesti G, et al; LEAD-G Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374:39-47.
7. US Food and Drug Administration. Medwatch exenatide 8/2009 update. Available at: Http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm124713. htm. Accessed for verification May 31, 2011.
8. Kingsnorth A, O'Reilly D. Acute pancreatitis. BMJ. 2006; 332:1072-1076. (Pubitemid 44365489)
9. Granger J, Remick D. Acute pancreatitis: Models, markers, and mediators. Shock. 2005;24(Suppl 1):45-51.
10. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330:1198-1210. (Pubitemid 24984692)
11. Nitsche CJ, Jamieson N, Lerch MM, Mayerle JV. Drug induced pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24:143-155.
12. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975;234:1236-1241.
13. Noel, RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2009;32:834-838.
14. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia. 2010; 53:21-26.
15. Raufman JP, Singh L, Singh G, Eng. J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267:21432-21437.
16. Matveyenko AV, Dry S, Cox HI, et al. Model of type 2 diabetes. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes. Interactions with metformin. Diabetes. 2009;58:1604-1615.
17. Elashoff M, Matveyenko AV, Grier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 based therapies. Gastroenterology. 2011. In Press.
18. European Association for the Study of Diabetes. EASD commentary on the publication by Elashoff et al., published online in Gastroenterology, February 2011: Increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy. Available at: Http://www.easd.org/ easdwebfiles/statements/Elashoff-Commentary.pdf. Accessed for verification May 31, 2011.
19. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: A case report. Diabetes Care. 2006;29:471. (Pubitemid 44106551)
20. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract. 2010; 16:80-83.
21. Nachnani JS, Bulchandani DG, Nookla A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53:153-159.
22. Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagon-like peptide-1 therapy and the exocrine pancreas: Innocent bystander or friendly fire? Diabetologia. 2010;53:1-6.
23. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: What you do not know can hurt you. Diabetes Care. 2010;33:453-455.
24. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care. 2010;33:428-433.
25. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. A retrospective observational pharmacy chain analysis. Diabetes Care. 2010;33:2349-2354.
26. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027.
27. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64: 984-990.
28. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 2009;58:2148-2161.
29. Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab. 2010;299: E1076-E1086.